TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01642719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-sleep restriction
Description: Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
Study: NCT03644316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BandGrip skin closure device
Description: topical skin closure device
Study: NCT03080701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto Mailing Plus Money
Description: Participant receives money as a thank you for completing CRC screening within 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto Mailing Plus Lottery
Description: Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
Study: NCT00696540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol diluted in hypertonic saline
Description: The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of salbutamol diluted in normal saline
Description: The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
Study: NCT02198898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUARDIX-SG
Study: NCT02322489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent Therapy
Description: Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
Study: NCT04448340

Intervention type: DIAGNOSTIC_TEST
Intervention: machine learning model
Description: Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.

Intervention type: DIAGNOSTIC_TEST
Intervention: machine learning model
Description: Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
Study: NCT01513694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral arthrodesis
Description: Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery.
Study: NCT03973502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA PET
Description: One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
Study: NCT00440102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate
Study: NCT04239573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04778865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D-correction
Description: Capsule with 50.000 UI cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D-RDA
Description: Capsule with 4.2000 UI cholecalciferol
Study: NCT00218816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nebulizer Education Intervention
Description: Asthma Education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Asthma Education Groups
Description: Asthma Education
Study: NCT04170530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT03106844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
Study: NCT03447899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Description: Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
Study: NCT02705014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone
Description: A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
Study: NCT05664347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal teach to goal education
Description: Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video based teach to goal education
Description: Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
Study: NCT03515551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCnyeso
Description: Weekly IV infusions of IMCnyeso

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCnyeso
Description: Weekly IV infusions of IMCnyeso
Study: NCT01037049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
Study: NCT03965468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: SBRT of all oligo-metastatic lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection - definitive local treatment.
Description: Surgical resection of primary tumour for patients with single station, non-bulky tumours.
Study: NCT02099292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab and DexaBEAM
Description: combination treatment
Study: NCT02994199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active video gaming
Description: Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
Study: NCT02607865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Oral administration once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral administration once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral administration once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral administration once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral administration once-daily
Study: NCT03227692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona Knee System
Description: Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona Knee System
Description: Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAssist Knee
Description: Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
Study: NCT01196091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo every 2 weeks
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo every 4 weeks
Description: Administered via subcutaneous injection for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study: NCT02221570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
Study: NCT02355665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Spray
Description: Nicotine Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match nicotine spray
Study: NCT03501381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
Study: NCT02968966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy regime
Description: Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
Study: NCT04121052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.
Study: NCT03965468

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy - definitive local treatment.
Description: Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
Study: NCT04121052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.
Study: NCT02322489

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham microcurrent therapy
Description: Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
Study: NCT04121052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive single dose of JNJ-64417184 as oral tablet.
Study: NCT03323086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) with Technology Extender
Description: One, 45-60 minute BI, followed by three months of access to technology extenders

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure
Description: Brochures provided one time
Study: NCT06187051

Intervention type: DEVICE
Intervention: FEVAR
Description: Relining the EVAR with FEVAR

Intervention type: DEVICE
Intervention: Explantation
Description: open surgery to explant the previous EVAR
Study: NCT03681873

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extremely Low Dose CT
Description: Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
Study: NCT01021839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grafts placement
Description: Graft placement (upper or lower extremity); surgical or radiographic revision as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grafts placement
Description: Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
Study: NCT00242710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogen
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogen
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CE 0.45 mg/MPA 1.5mg
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Study: NCT04272996

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Craniotomy only
Description: evacuation of SDH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy + Endovascular embolization of the middle meningeal vessels
Description: evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
Study: NCT06094686

Intervention type: DIAGNOSTIC_TEST
Intervention: epicardial adipose tissue thickness
Description: EATT measured via transthoracic echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: epicardial adipose tissue thickness
Description: EATT measured via transthoracic echocardiography
Study: NCT00718991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectranetics Turbo elite™ excimer laser catheter
Description: The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
Study: NCT04062240

Intervention type: DEVICE
Intervention: BIS sensor
Description: BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
Study: NCT01057394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopically guided PVI Ablation
Description: Endoscopically Guided Ablation using the EAS-AC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF PVI Ablation
Description: Radiofrequency ablation
Study: NCT05414669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Tablet 300 mg
Description: Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Placebo was given orally for a total of 3 days, beginning a day before ESWL.